Mental Health Bulletin, July 2008



[pic] [pic] [pic]

This bulletin covers aspects of lung cancer and should be of interest to multidisciplinary teams working in this area.

Sections can include:

• Combined Modality Therapies

• Drug Therapy

• Pathology, Staging, Polymorphisms & Biomarkers

• Prognosis, Survival & Risk Factors

• Radiotherapy & Imaging

• Supportive Care & Symptom Management

• Surgery

• Tobacco & Smoking

Many of the following articles are available online via the NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at knowledge.scot.nhs.uk/

If the article you require is not available via the NHS Scotland Knowledge Network and you would like to request a print copy, please submit your request online at quest.scot.nhs.uk

This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.

Compiled by:

Kirsty Coltart

Subject Librarian

Beatson West of Scotland Cancer Centre

0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk

General

Blanco R, Maestu I, de la Torre MG, et al. (2015). A review of the management of elderly patients with non-small-cell lung cancer. Annals of Oncology 26,3:451-463.

Campbell BA, Ball D and Mornex F. (2015). Multidisciplinary lung cancer meetings: improving the practice of radiation oncology and facing future challenges. Respirology 20,2:192-198.

Willers H, Stinchcombe TE, Barriger RB, et al. (2015). ACR Appropriateness Criteria Induction and Adjuvant Therapy for N2 Non-small-cell Lung Cancer. American Journal of Clinical Oncology 38,2:197-205.

Combined Modality Therapies

Bradley JD, Paulus R, Komaki R, et al. (2015). Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncology 16,2:187-199.

Cardenal F, Nadal E, Jove M, et al. (2015). Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature. Annals of Oncology 26,2:278-288.

Choy H, Gerber DE, Bradley JD, et al. (2015). Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. Lung Cancer 87,3:232-240.

Corso CD, Rutter CE, Wilson LD, et al. (2015). Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,1:148-155.

Garrido P, Engel-Riedel W, Serke M, et al. (2015). Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC). Lung Cancer 88,2:160-166.

Mokhles S, Verstegen N, Maat AP, et al. (2015). Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. Lung Cancer 87,3:283-289.

Williams M, Liu ZW, Hunter A, et al. (2015). An updated systematic review of lung chemo-radiotherapy using a new evidence aggregation method. Lung Cancer 87,3:290-295.

Drug & Targeted Therapy

Abe T, Takeda K, Ohe Y, et al. (2015). Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. Journal of Clinical Oncology 33,6:575-581.

Burdett S, Pignon JP, Tierney J, et al. (2015). Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database of Systematic Reviews 3,011430.

Burotto M, Manasanch EE, Wilkerson J, et al. (2015). Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 20,4:400-410.

Chiappori AA, Kolevska T, Spigel DR, et al. (2015). A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Annals of Oncology 26,2:354-362.

Choi YW, Ahn MS, Jeong GS, et al. (2015). Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?. Lung Cancer 87,2:155-161.

Doebele RC, Spigel D, Tehfe M, et al. (2015). Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer 121,6:883-892.

Gervais R, Le Caer H, Monnet I, et al. (2015). Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501. Clinical Lung Cancer 16,2:100-105.

Grilley-Olson JE, Keedy VL, Sandler A, et al. (2015). A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. Oncologist 20,2:105-106.

Hasegawa Y, Ando M, Maemondo M, et al. (2015). The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials. Oncologist 20,3:307-315.

Katsaounis P, Kotsakis A, Agelaki S, et al. (2015). Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemotherapy & Pharmacology 75,4:821-827.

Kotsakis A, Kentepozidis N, Emmanouilidis Ch, et al. (2015). Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). Lung Cancer 88,1:57-62.

Lu S, Li L, Luo Y, et al. (2015). A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,1:206-211.

Melichar B, Adenis A, Lockhart AC, et al. (2015). Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncology 16,4:395-405.

Novello S, Kaiser R, Mellemgaard A, et al. (2015). Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. European journal of cancer 51,3:317-326.

Paz-Ares L, Mezger J, Ciuleanu TE, et al. (2015). Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncology 16,3:328-337.

Ramalingam SS, Shtivelband M, Soo RA, et al. (2015). Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. Journal of Clinical Oncology 33,5:433-441.

Rizvi NA, Mazieres J, Planchard D, et al. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncology 16,3:257-265.

Scagliotti GV, Bondarenko I, Blackhall F, et al. (2015). Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Annals of Oncology 26,3:497-504.

Soejima K, Naoki K, Ishioka K, et al. (2015). A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. Cancer Chemotherapy & Pharmacology 75,3:513-519.

Spaans JN and Goss GD. (2015). Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer. Current opinion in oncology 27,2:102-107.

Spigel DR, Patel JD, Reynolds CH, et al. (2015). Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,2:353-359.

Waller CF, Vynnychenko I, Bondarenko I, et al. (2015). An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. Clinical Lung Cancer 16,2:92-99.

Yang JC, Wu YL, Schuler M, et al. (2015). Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology 16,2:141-151.

Zhao H, Fan Y, Ma S, et al. (2015). Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (INFORM; C-TONG 0804). Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,4:655-664.

Zinner RG, Obasaju CK, Spigel DR, et al. (2015). PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,1:134-142.

Pathology, Staging, Polymorphisms & Biomarkers

Oliver TG, Patel J and Akerley W. (2015). Squamous Non-small Cell Lung Cancer as a Distinct Clinical Entity. American Journal of Clinical Oncology 38,2:220-226.

Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, et al. (2015). Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer. Oncologist 20,3:316-322.

Petrosyan F, Daw H, Haddad A, et al. (2015). Gene expression profiling for early-stage NSCLC. American Journal of Clinical Oncology 38,1:103-107.

Um SW, Kim HK, Jung SH, et al. (2015). Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,2:331-337.

Varlotto JM, Yao AN, DeCamp MM, et al. (2015). Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival. International journal of radiation oncology, biology, physics 91,4:765-773.

Prognosis, Survival & Risk Factors

Blumenthal GM, Karuri SW, Zhang H, et al. (2015). Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses. Journal of Clinical Oncology 33,9:1008-1014.

Forrest LF, Adams J, Rubin G, et al. (2015). The role of receipt and timeliness of treatment in socioeconomic inequalities in lung cancer survival: population-based, data-linkage study. Thorax 70,2:138-145.

Franks KN, Jain P and Snee MP. (2015). Stereotactic ablative body radiotherapy for lung cancer. Clinical Oncology (Royal College of Radiologists) 27,5:280-289.

Radiotherapy & Imaging

Calais J, Thureau S, Dubray B, et al. (2015). Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer. Journal of Nuclear Medicine 56,2:196-203.

Huang K, Palma DA and IASLC Advanced Radiation Technology Committee. (2015). Follow-up of patients after stereotactic radiation for lung cancer: a primer for the nonradiation oncologist. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,3:412-419.

Kaster TS, Yaremko B, Palma DA, et al. (2015). Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature. Clinical Lung Cancer 16,2:71-79.

Li Y, Rodrigues A, Li T, et al. (2015). Impact of dose calculation accuracy during optimization on lung IMRT plan quality. Journal of Applied Clinical Medical Physics 16,1:5137.

Lievens Y, Obyn C, Mertens AS, et al. (2015). Stereotactic body radiotherapy for lung cancer: how much does it really cost?. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 10,3:454-461.

Ong P, Grosu H, Eapen GA, et al. (2015). Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Systematic Nodal Staging of Lung Cancer in Patients with N0 Disease by Computed Tomography and Integrated Positron Emission Tomography-Computed Tomography. Annals of the American Thoracic Society 12,3:415-419.

Pokhrel D, Badkul R, Jiang H, et al. (2015). Technical Note: Dosimetric evaluation of Monte Carlo algorithm in iPlan for stereotactic ablative body radiotherapy (SABR) for lung cancer patients using RTOG 0813 parameters. Journal of Applied Clinical Medical Physics 16,1:5058.

Porcel JM, Hernandez P, Martinez-Alonso M, et al. (2015). Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Chest 147,2:502-512.

Rintoul RC, Ahmed R, Dougherty B, et al. (2015). Linear endobronchial ultrasonography: a novelty turned necessity for mediastinal nodal assessment. Thorax 70,2:175-180.

Socha J, Guzowska A, Tyc-Szczepaniak D, et al. (2015). Accelerated hypofractionated thoracic radiotherapy in limited disease small cell lung cancer : comparison with the results of conventionally fractionated radiotherapy. Journal of B.U.On 20,1:146-157.

Stevens R, Macbeth F, Toy E, et al. (2015). Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database of Systematic Reviews 1,002143.

Yuan L, Wu QJ, Yin F, et al. (2015). Standardized beam bouquets for lung IMRT planning. Physics in Medicine & Biology 60,5:1831-1843.

Supportive Care & Symptom Management

Abdel-Rahman O and Fouad M. (2015). Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis. Expert Review of Anticancer Therapy 15,4:465-475.

Chen HM, Tsai CM, Wu YC, et al. (2015). Randomised controlled trial on the effectiveness of home-based walking exercise on anxiety, depression and cancer-related symptoms in patients with lung cancer. British journal of cancer 112,3:438-445.

Edvardsen E, Skjonsberg OH, Holme I, et al. (2015). High-intensity training following lung cancer surgery: a randomised controlled trial. Thorax 70,3:244-250.

Fernando HC, Landreneau RJ, Mandrekar SJ, et al. (2015). Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: Results from the ACOSOG Z4032 (Alliance) multicenter randomized trial. Journal of Thoracic & Cardiovascular Surgery 149,3:718-726.

Missel M, Schonau MN, Pedersen JH, et al. (2015). Transition from hospital to daily life: a pilot study. Rehabilitation Nursing Journal 40,1:20-29.

Pinna MA, Bruera E, Moralo MJ, et al. (2015). A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer. American Journal of Hospice & Palliative Medicine 32,3:298-304.

Salsman JM, Beaumont JL, Wortman K, et al. (2015). Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia. Supportive Care in Cancer 23,5:1355-1364.

Zhao H, Xie P, Li X, et al. (2015). A prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancer. Radiotherapy & Oncology 114,3:351-356.

Surgery

Cheng AM and Wood DE. (2015). Minimally invasive resection of early lung cancers. Oncology (Williston Park) 29,3:160-166.

Dell'Amore A, Monteverde M, Martucci N, et al. (2015). Lobar and sub-lobar lung resection in octogenarians with early stage non-small cell lung cancer: factors affecting surgical outcomes and long-term results. General Thoracic & Cardiovascular Surgery 63,4:222-230.

Riquet M, Rivera C, Pricopi C, et al. (2015). Is the lymphatic drainage of lung cancer lobe-specific? A surgical appraisal. European Journal of Cardio-Thoracic Surgery 47,3:543-549.

Zhang L, Li M, Yin R, et al. (2015). Comparison of the oncologic outcomes of anatomic segmentectomy and lobectomy for early-stage non-small cell lung cancer. Annals of Thoracic Surgery 99,2:728-737.

Zhang Y, Sun Y, Wang R, et al. (2015). Meta-analysis of lobectomy, segmentectomy, and wedge resection for stage I non-small cell lung cancer. Journal of surgical oncology 111,3:334-340.

Tobacco & Smoking

NICE. Quality Standard 82: Smoking: reducing tobacco use. March 2015

Please note that the journal articles you are accessing are subject to the terms and conditions imposed by the publisher, so there will be a limit on the number of articles an individual may download or print from a single issue of a journal. You can consult your local NHSGGC library with any queries.

If you have any questions regarding this or any other library services please contact Library staff – contact details are at the beginning of the bulletin.

Sources used for this bulletin: OVID databases, SIGN, NICE, Healthcare Improvement Scotland

-----------------------

Lung Cancer

April 2015

-----------------------

7

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download